{
    "root": "c0d7e550-fec4-42aa-9143-bc5600b8c3d3",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Tadalafil",
    "value": "20221001",
    "ingredients": [
        {
            "name": "TADALAFIL",
            "code": "742SXX0ICT"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "HYPROMELLOSE 2910 (15 MPA.S)",
            "code": "36SFW2JZ0W"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        }
    ],
    "indications": "tadalafil tablets phosphodiesterase 5 ( pde5 ) inhibitor indicated treatment : erectile dysfunction ( ed ) ( 1.1 ) signs symptoms benign prostatic hyperplasia ( bph ) ( 1.2 ) ed signs symptoms bph ( ed/bph ) ( 1.3 ) tadalafil tablets used finasteride initiate bph treatment , recommended 26 weeks ( 1.4 ) .",
    "contraindications": "split tadalafil tablets ; entire dose taken .",
    "warningsAndPrecautions": "tadalafil tablets , usp supplied follows : 2.5 mg light yellow , oval-shaped , film-coated tablets , debossed ‘ 08 ’ one side plain side . carton 30 tablets ( 2 blister cards 15 tablets ) ndc 0480-2308-65 5 mg pale yellow , oval-shaped , film-coated tablets , debossed ‘ 09 ’ one side plain side . carton 30 tablets ( 2 blister cards 15 tablets ) ndc 0480-2309-65 bottles 30 ndc 0480-2309-56 10 mg pale yellow , oval-shaped , film-coated tablets , debossed ‘ 10 ’ one side plain side . bottles 30 ndc 0480-2310-56 20 mg pale yellow , oval-shaped , film-coated tablets , debossed ‘ 11 ’ one side plain side . bottles 30 ndc 0480-2311-56",
    "adverseReactions": "nitrates concomitant nitrates form contraindicated [ ( 4.1 ) ] . alpha-blockers ed — tadalafil tablets coadministered alpha-blocker patients treated ed , patients stable alpha-blocker therapy prior initiating treatment , tadalafil tablets initiated lowest recommended dose [ ( 5.6 ) , ( 7.1 ) , pharmacology ( 12.2 ) ] . bph — tadalafil tablets recommended combination alpha-blockers treatment bph [ ( 5.6 ) , ( 7.1 ) , pharmacology ( 12.2 ) ] . cyp3a4 inhibitors tadalafil tablets needed — patients taking concomitant potent inhibitors cyp3a4 , ketoconazole ritonavir , maximum recommended dose tadalafil tablets 10 mg , exceed every 72 hours [ ( 5.10 ) ( 7.2 ) ] . tadalafil tablets daily — patients taking concomitant potent inhibitors cyp3a4 , ketoconazole ritonavir , maximum recommended dose 2.5 mg [ ( 5.10 ) ( 7.2 ) ] .",
    "indications_original": "Tadalafil tablets are a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of: erectile dysfunction (ED) ( 1.1 ) the signs and symptoms of benign prostatic hyperplasia (BPH) ( 1.2 ) ED and the signs and symptoms of BPH (ED/BPH) ( 1.3 ) If tadalafil tablets are used with finasteride to initiate BPH treatment, such use is recommended for up to 26 weeks ( 1.4 ).",
    "contraindications_original": "Do not split tadalafil tablets; entire dose should be taken.",
    "warningsAndPrecautions_original": "Tadalafil tablets, USP are supplied as follows: \n                        2.5 mg light yellow, oval-shaped, film-coated tablets, debossed with ‘08’ on one side and plain on the other side. \n                        Carton of 30 tablets (2 blister cards of 15 tablets)     NDC 0480-2308-65\n                        5 mg pale yellow, oval-shaped, film-coated tablets, debossed with ‘09’ on one side and plain on the other side.\n                        Carton of 30 tablets (2 blister cards of 15 tablets)     NDC 0480-2309-65\n                        Bottles of 30                                                               NDC 0480-2309-56\n                        10 mg pale yellow, oval-shaped, film-coated tablets, debossed with ‘10’ on one side and plain on the other side.\n                        Bottles of 30                                                               NDC 0480-2310-56\n                        20 mg pale yellow, oval-shaped, film-coated tablets, debossed with ‘11’ on one side and plain on the other side.\n                        Bottles of 30                                                               NDC 0480-2311-56",
    "adverseReactions_original": "Nitrates\n                  \n                  Concomitant use of nitrates in any form is contraindicated [see Contraindications (4.1)].\n                  \n                     Alpha-Blockers\n                     \n                  \n                  \n                     ED — When tadalafil tablets are coadministered with an alpha-blocker in patients being treated for ED, patients should be stable on alpha-blocker therapy prior to initiating treatment, and tadalafil tablets should be initiated at the lowest recommended dose [see Warnings and Precautions (5.6), Drug Interactions (7.1), and Clinical Pharmacology (12.2)].\n                  \n                     BPH — Tadalafil tablets are not recommended for use in combination with alpha-blockers for the treatment of BPH [see Warnings and Precautions (5.6), Drug Interactions (7.1), and Clinical Pharmacology (12.2)].\n                  \n                  \n                     CYP3A4 Inhibitors\n                  \n                  \n                     Tadalafil Tablets for Use as Needed — For patients taking concomitant potent inhibitors of CYP3A4, such as ketoconazole or ritonavir, the maximum recommended dose of tadalafil tablets is 10 mg, not to exceed once every 72 hours [see Warnings and Precautions (5.10) and Drug Interactions (7.2)].\n                  \n                     Tadalafil Tablets for Once Daily Use — For patients taking concomitant potent inhibitors of CYP3A4, such as ketoconazole or ritonavir, the maximum recommended dose is 2.5 mg [see Warnings and Precautions (5.10) and Drug Interactions (7.2)]."
}